|
|
Volumn 15 Suppl 1, Issue , 2010, Pages 49-57
|
|
Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
TRASTUZUMAB;
ARTICLE;
BREAST TUMOR;
CLINICAL TRIAL;
COST BENEFIT ANALYSIS;
DRUG COST;
ECONOMICS;
HEALTH INSURANCE;
HUMAN;
NEOPLASM;
ONCOLOGY;
ORGANIZATION;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
CLINICAL TRIALS AS TOPIC;
COST-BENEFIT ANALYSIS;
DRUG COSTS;
HUMANS;
INSURANCE, HEALTH;
MEDICAL ONCOLOGY;
NEOPLASMS;
ORGANIZATIONAL INNOVATION;
|
|
EID: 77954653640
PISSN: None
EISSN: 1549490X
Source Type: Journal
DOI: 10.1634/theoncologist.2010-S1-49 Document Type: Article |
|
Times cited : (18)
|
|
References (0)
|